TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34044407

Group type: EXPERIMENTAL
Intervention: Divaza
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 33032234

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with systemic antibiotics (PT1 group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy without antibiotics (PT2 group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (CG) with no periodontal therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treatment groups (PT1 and PT2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 34420873

Group type: EXPERIMENTAL
Intervention: Dorsal approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 20
Study: 34080247

Group type: EXPERIMENTAL
Intervention: Health and lifestyle modification intervention (n = 59)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care (n = 62)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Health and lifestyle modification intervention
Number of subjects: 121
Study: 32811843

Group type: EXPERIMENTAL
Intervention: ADV7103 (alkalising agent) at doses of 1.44 meq/kg twice a day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 35427760

Group type: EXPERIMENTAL
Intervention: 30‐day smartphone‐based mindfulness meditation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Problem‐solving control program
Number of subjects: 0
Study: 33464412

Group type: EXPERIMENTAL
Intervention: MI of ankle plantarflexion (MI-PF)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MI of ankle dorsiflexion (MI-DF)
Number of subjects: 23

Group type: COMPARATOR
Intervention: MI of ankle dorsiflexion (MI-DF) after 10 min practice
Number of subjects: 23

Group type: COMPARATOR
Intervention: Resting condition
Number of subjects: 23
Study: 32938447

Group type: EXPERIMENTAL
Intervention: Neuropalliative care intervention
Number of subjects: 151
Study: 36153625

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 4 mg/kg/h continuous infusion)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline solution (same volumes as lidocaine)
Number of subjects: 300
Study: 32278783

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5898
Study: 35718070

Group type: EXPERIMENTAL
Intervention: GEADS (AI-assisted diagnosis system)
Number of subjects: 11
Study: 33599356

Group type: EXPERIMENTAL
Intervention: E6011 (anti-fractalkine antibody) 2, 5, 10, and 15 mg/kg intravenously every 2 weeks during the 12-week multiple ascending dose phase.
Number of subjects: 28
Study: 33289953

Group type: EXPERIMENTAL
Intervention: AGS‐16C3F 1.8 mg/kg every 3 weeks
Number of subjects: 133

Group type: COMPARATOR
Intervention: Axitinib 5 mg twice daily (starting dose)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: AGS‐16C3F
Number of subjects: 133

Group type: COMPARATOR
Intervention: Axitinib
Number of subjects: 133
Study: 33104490

Group type: EXPERIMENTAL
Intervention: Direct Transfer to Angio-Suite (DTAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computed Tomography-Transit (CTT)
Number of subjects: 0
Study: 35428315

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 498
Study: 33922334

Group type: EXPERIMENTAL
Intervention: Intervention group with visual and oral instructor prompts to stand
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group with no prompts
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 48
Study: 32807208

Group type: EXPERIMENTAL
Intervention: Protac Ball Blanket™ (PBB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 45
Study: 33162389

Group type: EXPERIMENTAL
Intervention: Vascular ultrasound examination in the carotid and femoral arteries assessing 12 territories, combined with clinical, anthropometric, lifestyle, and biochemical parameters.
Number of subjects: 8330
Study: 32999269

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 300
Study: 36278178

Group type: EXPERIMENTAL
Intervention: Brazilian Organic Propolis (BOP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32954688

Group type: EXPERIMENTAL
Intervention: Sina curcumin capsules 80 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 35464292

Group type: EXPERIMENTAL
Intervention: Intravenous dasiglucagon (doses ranged from 0.03 mg to 1.5 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous dasiglucagon (0.6 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 60
Study: 34266452

Group type: EXPERIMENTAL
Intervention: Aspirin, Atorvastatin, Nicorandil (Aspirin 325 mg starting dose, 75 mg once daily; Atorvastatin 40 mg starting dose, 40 mg once daily; Nicorandil 10 mg starting dose, 5 mg twice daily) plus conventional therapy
Number of subjects: 396

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 396
Study: 36397132

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine, administered in three monthly rounds at the beginning of the malaria transmission season.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mosquitoes fed on blood from IVM-treated individuals.
Number of subjects: 32
Study: 35605609

Group type: EXPERIMENTAL
Intervention: Pramipexole (dose titrated from 0.25 mg/d to 1.0 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33223140

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 32863329

Group type: EXPERIMENTAL
Intervention: Hybrid Training System (HTS)
Number of subjects: 18
Study: 35750681

Group type: EXPERIMENTAL
Intervention: IBI362 (3.0 mg, 4.5 mg or 6.0 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IBI362
Number of subjects: 43
Study: 35611762

Group type: EXPERIMENTAL
Intervention: 52% low-sodium salt and DASH diet
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal salt and DASH diet
Number of subjects: 61
Study: 34740373

Group type: EXPERIMENTAL
Intervention: HENRY plus the implementation optimisation intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: HENRY alone (control)
Number of subjects: 20
Study: 32674447

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Topical clobetasol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Topical budesonide
Number of subjects: 76
Study: 34785390

Group type: EXPERIMENTAL
Intervention: Baseline autonomy scores in patients who reported Spanish as their primary language
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Baseline autonomy scores in patients with diabetes
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Baseline autonomy scores in patients with depressive symptoms
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Autonomy scores of Non-Hispanic White participants compared to Non-Hispanic Black participants
Number of subjects: 295
Study: 33632194

Group type: EXPERIMENTAL
Intervention: Game jam intervention to create an educational game on cultural safety
Number of subjects: 531

Group type: COMPARATOR
Intervention: Standard lesson plus an interactive workshop on cultural safety
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Game jam intervention
Number of subjects: 531
Study: 32550229

Group type: EXPERIMENTAL
Intervention: Health-Promoting Lifestyle Education Intervention (HPLEI) for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no planned education programme)
Number of subjects: 72
Study: 35533885

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent financial incentives (FI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled trials of abstinence-contingent financial incentives (FI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (Best Practices alone and noncontingent payments)
Number of subjects: 0
Study: 35814305

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT) with oral drug treatment
Number of subjects: 143

Group type: COMPARATOR
Intervention: Oral drug treatment only (Control)
Number of subjects: 143
Study: 32223331

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Fibro-α Scores
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: GUCI
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: King Score
Number of subjects: 405
Study: 35038723

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg maintenance dose every 3 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg maintenance dose every 3 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 2.0 g/kg maintenance dose every 3 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Induction dose alone
Number of subjects: 142

Group type: COMPARATOR
Intervention: 0.5 g/kg maintenance dose
Number of subjects: 142

Group type: COMPARATOR
Intervention: 1.0 g/kg maintenance dose
Number of subjects: 142

Group type: COMPARATOR
Intervention: 2.0 g/kg maintenance dose
Number of subjects: 142
Study: 34078307

Group type: EXPERIMENTAL
Intervention: Hope-oriented group counseling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 60
Study: 32812177

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 41)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (n = 47)
Number of subjects: 89
Study: 34153943

Group type: EXPERIMENTAL
Intervention: Experimental therapies with statistically significant OS endpoints (56 trials)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Experimental therapies with non-significant OS endpoints (131 trials)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Experimental therapies with PRS endpoints (total analyzed: 216)
Number of subjects: 362
Study: 32375151

Group type: EXPERIMENTAL
Intervention: Robo-Cob technique
Number of subjects: 25

Group type: COMPARATOR
Intervention: CELL technique (control)
Number of subjects: 25
Study: 35362709

Group type: EXPERIMENTAL
Intervention: Modified surgical approach (Method for surgical treatment of odontogenic oral phlegmon of mouth floor with partial dissection of sublingual‐submandibular sac)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Modified surgical approach
Number of subjects: 86
Study: 33627633

Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCAA) and tyrosine
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Betaine and choline
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Clinical model including metabolite factors
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Baseline levels of metabolites in BCAA and TMAO-microbiome-related pathways
Number of subjects: 173
Study: 34260606

Group type: EXPERIMENTAL
Intervention: Cognitively engaging active breaks
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study: 32511803

Group type: EXPERIMENTAL
Intervention: D1 Now intervention (support-worker, interactive messaging system, agenda setting tool)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control arm
Number of subjects: 0
Study: 35301018

Group type: EXPERIMENTAL
Intervention: Video-based anticipatory guidance at well-child visits
Number of subjects: 0
Study: 33394691

Group type: EXPERIMENTAL
Intervention: Single-vessel CTO PCI
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Multivessel PCI
Number of subjects: 1000
Study: 32175988

Group type: EXPERIMENTAL
Intervention: MAP maintained at 60 to 65 mmHg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MAP maintained at 80 to 85 mmHg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MAP maintained at 70 to 75 mmHg
Number of subjects: 22
Study: 36477637

Group type: EXPERIMENTAL
Intervention: Closed-suction group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open-suction group
Number of subjects: 80
Study: 35606020

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic and associated lockdown measures
Number of subjects: 437
Study: 34667852

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34751780

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 33325799

Group type: EXPERIMENTAL
Intervention: RT234 (vardenafil inhalation powder) single doses of 0.2-2.4 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RT234 (vardenafil inhalation powder) repeated doses of up to 2.4 mg q4h for four doses daily for 9 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RT234 (vardenafil inhalation powder)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 20 mg vardenafil tablets (Levitra®)
Number of subjects: 32
Study: 34187823

Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation programme (10-session mindfulness-based and acceptance-based group programme followed by 12 weeks of physical activity counselling)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Treatment as usual (no treatment or any other treatment of their choice)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation programme
Number of subjects: 170

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 170
Study: 32611865

Group type: EXPERIMENTAL
Intervention: Novel herbal anesthetic gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2% lignocaine gel
Number of subjects: 30
Study: 34993962

Group type: EXPERIMENTAL
Intervention: Recalling a special moment from high school
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recalling an ordinary event from high school
Number of subjects: 0
Study: 33783506

Group type: EXPERIMENTAL
Intervention: Oral doxycycline
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intramuscular procaine G penicillin
Number of subjects: 87
Study: 32866148

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Core muscle training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (CG) - No core muscle training
Number of subjects: 16
Study: 35553371

Group type: EXPERIMENTAL
Intervention: Interval Exercise (IE)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Accumulated Exercise (AE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuous Exercise (CE)
Number of subjects: 44
Study: 36121357

Group type: EXPERIMENTAL
Intervention: Intensive care management
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 131
Study: 32926603

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) starting at 20 mg/d and titrated to a maximum of 70 mg/d
Number of subjects: 35

Group type: COMPARATOR
Intervention: Behavioral Parent Training (BPT)
Number of subjects: 35
Study: 35930284

Group type: EXPERIMENTAL
Intervention: ETC-assigned facilities
Number of subjects: 6062
Study: 33513650

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) in septic shock
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High volume TPE in acute liver failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy containing anticoagulation, corticosteroids, and TPE or intravenous immunoglobulin in CAPS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPE for thyrotoxic storm
Number of subjects: 0
Study: 33479025

Group type: COMPARATOR
Intervention: Arm A (6MHP + IFA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arm B (6MHP + IFA + mCy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arm C (6MHP + IFA + polyICLC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arm D (6MHP + IFA + polyICLC + mCy)
Number of subjects: 48
Study: 32513684

Group type: EXPERIMENTAL
Intervention: Treatment effect heterogeneity across baseline risk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic models for RCT enrollment and treatment choice decisions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distribution of risk within RCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate of change of baseline risk over time
Number of subjects: 0
Study: 35580835

Group type: EXPERIMENTAL
Intervention: Needle-free local anaesthesia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional local anaesthetic
Number of subjects: 8

Group type: COMPARATOR
Intervention: Needle-free local anaesthesia and Conventional local anaesthetic
Number of subjects: 8
Study: 33234644

Group type: EXPERIMENTAL
Intervention: Medicines at Transitions Intervention (MaTI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35403394

Group type: EXPERIMENTAL
Intervention: Cluster acupuncture at scalp points (Qianding to Baihui, Xinhui to Qianding), once a day, 5 days a week for 4 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cluster acupuncture at scalp points
Number of subjects: 72

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 72
Study: 33551214

Group type: EXPERIMENTAL
Intervention: Timolol maleate gel (Timoptol® LP 0.5%) applied every 2 days for 12 weeks as adjuvant therapy to standard care.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care alone (interface dressing and multilayer venous compression).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Timolol maleate gel (Timoptol® LP 0.5%) applied every 2 days for 12 weeks.
Number of subjects: 40
Study: 32876010

Group type: EXPERIMENTAL
Intervention: Isoniazid 900 mg given twice weekly for 12 months
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study: 34657346

Group type: EXPERIMENTAL
Intervention: Exergaming (interactive cycling at least twice a week for 6 months)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (regular activities)
Number of subjects: 112
Study: 33641012

Group type: EXPERIMENTAL
Intervention: TLPLDC vaccine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (empty yeast cell wall particles and autologous dendritic cells)
Number of subjects: 144
Study: 35841316

Group type: EXPERIMENTAL
Intervention: TS <7.8 cm training cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TS ≥7.8 cm training cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomograms for TS <7.8 cm and TS ≥7.8 cm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation cohorts
Number of subjects: 0
Study: 33409540

Group type: EXPERIMENTAL
Intervention: Treatment with steroids, six food elimination diet, mesalamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diagnosis of autistic spectrum disorder (ASD)
Number of subjects: 50
Study: 35679831

Group type: EXPERIMENTAL
Intervention: LAight® therapy (8 sessions during period B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: LAight® therapy (group TC + L/L)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: LAight® therapy (group TC/L)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Topical clindamycin 1% solution (group TC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Topical clindamycin 1% solution combined with LAight® therapy (group TC + L)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: LAight® therapy (during period B)
Number of subjects: 88
Study: 33759656

Group type: EXPERIMENTAL
Intervention: Hemicraniectomy (surgery)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 151
Study: 34396868

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flank position
Number of subjects: 60
Study: 32852967

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy with higher affiliative behaviors
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy with nonreciprocal relationship in dominance dimension
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy with complementarity in dominance dimension
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy with interpersonal problems of communion
Number of subjects: 90
Study: 36415151

Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LPS administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of glucose and LPS
Number of subjects: 10
Study: 616505213

Group type: EXPERIMENTAL
Intervention: Intraoperative injection of botulinum toxin A (BTA) in the orbicularis muscle below the lower punctum of both eyes (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraoperative insertion of temporary extended duration silicone punctal plugs in the lower punctum of both eyes (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional medical treatment with preservative‐free tear substitutes only (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Punctal plugs (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) (group B)
Number of subjects: 60
Study: 34268372

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 24
Study: 33028455

Group type: EXPERIMENTAL
Intervention: Lay idiom ('problems with your emotions or nerves')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical idiom ('problems with your mental health')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical idiom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lay idiom
Number of subjects: 0
Study: 34217570

Group type: EXPERIMENTAL
Intervention: early-DTP vaccination
Number of subjects: 2398

Group type: COMPARATOR
Intervention: no-DTP vaccination
Number of subjects: 2398
Study: 34243101

Group type: EXPERIMENTAL
Intervention: GranaGard for 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GranaGard for 3 months, followed by placebo for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 30